Amarin has successfully achieved target patient enrollment in the North American Phase III clinical trial of Miraxion in Huntington's disease (HD).

The target of three hundred randomized patients with HD in the TREND study, which is being conducted by the Huntington Study Group at 42 neurology centers in the U.S. and Canada, has been met. The trial is evaluating the effects of Miraxion compared to placebo using the Total Motor Score-4 subscale of the Unified Huntington's Disease Rating Scale (UHDRS). It is hoped that patients treated with Miraxion at a dose of 2 g per day (1 g twice daily) for six months will demonstrate significant improvements in their motor functioning as measured by TMS-4.